JP2017527582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527582A5 JP2017527582A5 JP2017513488A JP2017513488A JP2017527582A5 JP 2017527582 A5 JP2017527582 A5 JP 2017527582A5 JP 2017513488 A JP2017513488 A JP 2017513488A JP 2017513488 A JP2017513488 A JP 2017513488A JP 2017527582 A5 JP2017527582 A5 JP 2017527582A5
- Authority
- JP
- Japan
- Prior art keywords
- lif
- pharmaceutical composition
- agent
- composition according
- antagonizes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 33
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- 229940127089 cytotoxic agent Drugs 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 101710113436 GTPase KRas Proteins 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 7
- 229960005277 gemcitabine Drugs 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000012829 chemotherapy agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048770P | 2014-09-10 | 2014-09-10 | |
| US62/048,770 | 2014-09-10 | ||
| PCT/US2015/049461 WO2016040657A1 (en) | 2014-09-10 | 2015-09-10 | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017527582A JP2017527582A (ja) | 2017-09-21 |
| JP2017527582A5 true JP2017527582A5 (OSRAM) | 2018-10-18 |
Family
ID=55459579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513488A Pending JP2017527582A (ja) | 2014-09-10 | 2015-09-10 | Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20170247446A1 (OSRAM) |
| EP (1) | EP3191129A4 (OSRAM) |
| JP (1) | JP2017527582A (OSRAM) |
| CN (1) | CN106687134A (OSRAM) |
| AU (1) | AU2015314980A1 (OSRAM) |
| CA (1) | CA2958685A1 (OSRAM) |
| WO (1) | WO2016040657A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173483A1 (en) * | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| EP3407820A4 (en) | 2016-01-26 | 2019-11-06 | Cyberdontics, Inc. | Automated dental treatment system |
| MX2019007376A (es) | 2016-12-19 | 2020-02-07 | Mosaic Biomedicals S L U | Anticuerpos contra el lif y usos de los mismos. |
| US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| JP7423598B2 (ja) * | 2018-04-12 | 2024-01-29 | メドイミューン・リミテッド | がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ |
| WO2019215512A1 (en) | 2018-05-10 | 2019-11-14 | Cyberdontics Inc. | Automated dental drill |
| CN112638941A (zh) * | 2018-05-14 | 2021-04-09 | 免疫医疗有限公司 | 针对lif的抗体及其剂量形式 |
| WO2019243900A2 (en) * | 2018-06-18 | 2019-12-26 | Mosaic Biomedicals Slu | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| WO2020219668A1 (en) * | 2019-04-24 | 2020-10-29 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treating ras-mutant cancers |
| EP4208122A4 (en) | 2020-09-03 | 2024-09-11 | Perceptive Technologies, Inc. | METHOD AND DEVICE FOR CNA ANALYSIS OF DENTAL ANATOMY |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| KR20140126357A (ko) * | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
| EP3049110A2 (en) * | 2013-09-23 | 2016-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for targeting tumor microenvironment and for preventing metastasis |
-
2015
- 2015-09-10 CA CA2958685A patent/CA2958685A1/en not_active Abandoned
- 2015-09-10 JP JP2017513488A patent/JP2017527582A/ja active Pending
- 2015-09-10 US US15/508,036 patent/US20170247446A1/en not_active Abandoned
- 2015-09-10 AU AU2015314980A patent/AU2015314980A1/en not_active Abandoned
- 2015-09-10 EP EP15840805.4A patent/EP3191129A4/en not_active Withdrawn
- 2015-09-10 CN CN201580048473.1A patent/CN106687134A/zh active Pending
- 2015-09-10 WO PCT/US2015/049461 patent/WO2016040657A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527582A5 (OSRAM) | ||
| Mei et al. | Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand | |
| JP2007526455A5 (OSRAM) | ||
| CY1120903T1 (el) | Ενωσεις αμινοπυριδυλοξυπυραζολιου | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| JP2015532292A5 (OSRAM) | ||
| JP2017517520A5 (OSRAM) | ||
| JP2016536361A5 (OSRAM) | ||
| JP2017537070A5 (OSRAM) | ||
| NZ739902A (en) | Multiligand agent for drug delivery | |
| JP2013173775A5 (OSRAM) | ||
| FI4403228T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| JP2013520442A5 (OSRAM) | ||
| JP2016513657A5 (OSRAM) | ||
| JP2013523843A5 (OSRAM) | ||
| JP2017533222A5 (OSRAM) | ||
| JP2016525097A5 (OSRAM) | ||
| JP2019506392A5 (OSRAM) | ||
| JP2019533651A5 (OSRAM) | ||
| JP2019532047A5 (OSRAM) | ||
| JP2018522028A5 (OSRAM) | ||
| RU2018127640A (ru) | Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников | |
| JP2013541586A5 (OSRAM) | ||
| JP2021501150A5 (OSRAM) | ||
| JP2017513902A5 (OSRAM) |